Karen Neuendorff - Brii Biosciences Chief HR
| BRIBF Stock | USD 0.30 0.17 130.77% |
Insider
Karen Neuendorff is Chief HR of Brii Biosciences Limited
| Web | https://www.briibio.com |
Brii Biosciences Management Efficiency
The company has return on total asset (ROA) of (0.1877) % which means that it has lost $0.1877 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (5.3439) %, meaning that it generated substantial loss on money invested by shareholders. Brii Biosciences' management efficiency ratios could be used to measure how well Brii Biosciences manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Andreas Bergthaler | Hookipa Pharma | N/A | |
| Reinhard Kandera | Hookipa Pharma | 55 | |
| Steven MD | Cabaletta Bio | 64 | |
| Rohan Palekar | 89bio Inc | 59 | |
| Timothy Rolph | Akero Therapeutics | 71 | |
| Kerry MD | Terns Pharmaceuticals | N/A | |
| Harry MD | 89bio Inc | 60 | |
| Aimee MD | Cabaletta Bio | N/A | |
| Samik MD | Cabaletta Bio | N/A | |
| Ian Clements | Mirum Pharmaceuticals | 55 | |
| Louise RodinoKlapac | Sarepta Therapeutics | 47 | |
| MA MS | Inozyme Pharma | N/A | |
| Heather MSc | Cabaletta Bio | N/A | |
| Charles II | Day One Biopharmaceuticals | 47 | |
| Manuel Dafonseca | Sonnet Biotherapeutics Holdings | N/A | |
| Christine MBA | Hookipa Pharma | 59 | |
| Lukas Flatz | Hookipa Pharma | N/A | |
| Klaus Orlinger | Hookipa Pharma | 47 | |
| Jason Davis | Virax Biolabs Group | 53 | |
| Meeshanthini Dogan | Cardio Diagnostics Holdings | 36 | |
| Susan Dexter | Sonnet Biotherapeutics Holdings | 70 | |
Management Performance
| Return On Equity | -5.34 | |||
| Return On Asset | -0.19 |
Brii Biosciences Leadership Team
Elected by the shareholders, the Brii Biosciences' board of directors comprises two types of representatives: Brii Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Brii. The board's role is to monitor Brii Biosciences' management team and ensure that shareholders' interests are well served. Brii Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Brii Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Lianhong Xu, Head Discovery | ||
| Zhi Hong, Ex Cofounder | ||
| CFA JD, Company Officer | ||
| Karen Neuendorff, Chief HR | ||
| Li MD, Chief Officer | ||
| Qing Zhu, Head RD | ||
| Coy Stout, Head Advocacy | ||
| Eleanor Groot, Chief Officer | ||
| Susannah Cantrell, Chief Officer | ||
| MPH MD, VP Area |
Brii Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Brii Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -5.34 | |||
| Return On Asset | -0.19 | |||
| Operating Margin | (10.33) % | |||
| Current Valuation | 305.78 M | |||
| Shares Outstanding | 723.35 M | |||
| Shares Owned By Insiders | 5.41 % | |||
| Shares Owned By Institutions | 53.10 % | |||
| Price To Book | 0.95 X | |||
| Price To Sales | 10.64 X | |||
| Gross Profit | 92.54 M |
Currently Active Assets on Macroaxis
Other Information on Investing in Brii Pink Sheet
Brii Biosciences financial ratios help investors to determine whether Brii Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Brii with respect to the benefits of owning Brii Biosciences security.